Regulation of IL-10 by Herbal and Hormonal Therapy: The Impact of Eleutherine Bulbosa and Tamoxifen in an Experimental Breast Cancer Model Effects of Eleutherine bulbosa–Tamoxifen on interleukin-10

Rahmi (1), andi nilawati usman (2), Risfah Yulanty (3), Stang (4), Andi Ariyandy (5)
(1) Department of Midwifery, Graduate School, Hasanuddin University, Makassar, South Sulawesi, Indonesia, Indonesia,
(2) hasanuddin university, Indonesia,
(3) Department of Pharmacy, Faculty of Pharmacy, Hasanuddin University, Makassar, South Sulawesi, Indonesia, Indonesia,
(4) Department of Public Health, Faculty of Public Health, Hasanuddin University, Makassar, South Sulawesi, Indonesia, Indonesia,
(5) Department of Physiology, Faculty of Medicine, Hasanuddin University, Makassar, South Sulawesi, Indonesia, Indonesia

Abstract

Background: Breast cancer is the most common cancer affecting women worldwide, with the number of cases and deaths continuing to rise. This study focuses on evaluating the single and combined effects of Eleutherine bulbosa ethanol extract and tamoxifen in reducing interleukin-10 levels in BALB/c mice with breast cancer models.


Methods: This study used a laboratory experimental approach with a post-test-only control group design, using 36 female Mus musculus BALB/c strain mice (aged 8-10 weeks) and randomly divided into six groups: negative and positive control groups. The intervention groups were given Eleutherine bulbosa ethanol extract at a dose of 180 mg/kg BW every 14 days, tamoxifen was given at a dose of 10 mg/kg BW every 2 days for 7 days within a 14-day period, a combination of Eleutherine bulbosa ethanol extract and tamoxifen, and tamoxifen and Eleutherine bulbosa ethanol extract. Effectiveness was evaluated based on interleukin-10 levels in serum.


Results: The study found that the combination of Eleutherine bulbosa ethanol extract and tamoxifen significantly reduced Interleukin-10 levels in BALB/c mice with breast cancer modeling. The extract  Eleutherine bulbosa ethanol extract reduced Interleukin-10 by 31.4%, while tamoxifen reduced it by 59.1%. The strongest synergistic effect was observed when combined with tamoxifen, reducing Interleukin-10 levels by 64.6%, indicating its effectiveness in suppressing the immunosuppressive response supporting tumor growth.


Conclusion: Tamoxifen and Eleutherine bulbosa extract showed synergistic effects in reducing IL-10 levels, suggesting enhanced immunomodulatory action compared to monotherapy. This technique could enhance breast cancer treatment efficacy by diminishing immunosuppression.

Full text article

Generated from XML file

References

Bakhsh T, Alyami NM. Inducing breast cancer cell death: The impact of taxodone on proliferation through apoptosis. Heliyon. 2024 Jul;10(13):e34044. https://doi.org/10.1016/j.heliyon.2024.e34044

Breast [Internet]. American Cancer Society. [cited 2024 Nov 1]. Available from: https://cancerstatisticscenter.cancer.org/types/breast

Katalog Data - Layanan Permintaan Data | Kementerian Kesehatan RI [Internet]. [cited 2024 Oct 20]. Available from: https://layanandata.kemkes.go.id/katalog-data/ski/ketersediaan-data/ski-2023

Vilchis-Landeros MM, Vázquez-Meza H, Vázquez-Carrada M, Uribe-Ramírez D, Matuz-Mares D. Antioxidant Enzymes and Their Potential Use in Breast Cancer Treatment. Int J Mol Sci. 2024 May 23;25(11):5675. https://doi.org/10.3390/ijms25115675

Dubey A, Sharma B. Targeting Oxidative Stress Biomarkers in Breast Cancer Development and the Potential Protective Effect of Phytochemicals. Drugs Drug Candidates. 2025 May 23;4(2):23. https://doi.org/10.3390/ddc4020023

Carlini V, Noonan DM, Abdalalem E, Goletti D, Sansone C, Calabrone L, et al. The multifaceted nature of IL-10: regulation, role in immunological homeostasis and its relevance to cancer, COVID-19 and post-COVID conditions. Front Immunol. 2023 Jun 8;14:1161067. https://doi.org/10.3389/fimmu.2023.1161067

Islam H, Chamberlain TC, Mui AL, Little JP. Elevated Interleukin-10 Levels in COVID-19: Potentiation of Pro-Inflammatory Responses or Impaired Anti-Inflammatory Action? Front Immunol. 2021 Jun 21;12:677008. https://doi.org/10.3389/fimmu.2021.677008

Sun H, Wu Y, Zhang Y, Ni B. IL-10-Producing ILCs: Molecular Mechanisms and Disease Relevance. Front Immunol [Internet]. 2021 Mar 29 [cited 2025 Jun 23];12. Available from: https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2021.650200/full. https://doi.org/10.3389/fimmu.2021.650200

Heimes AS, Shehaj I, Almstedt K, Krajnak S, Schwab R, Stewen K, et al. Prognostic Impact of Acute and Chronic Inflammatory Interleukin Signatures in the Tumor Microenvironment of Early Breast Cancer. Int J Mol Sci. 2024 Oct 16;25(20):11114. https://doi.org/10.3390/ijms252011114

Raheem F, Karikalan SA, Batalini F, El Masry A, Mina L. Metastatic ER+ Breast Cancer: Mechanisms of Resistance and Future Therapeutic Approaches. Int J Mol Sci. 2023 Nov 11;24(22):16198. https://doi.org/10.3390/ijms242216198

Zhuo Z, Zhang D, Lu W, Wu X, Cui Y, Zhang W, et al. Reversal of tamoxifen resistance by artemisinin in ER+ breast cancer: bioinformatics analysis and experimental validation. Oncol Res. 2024;32(6):1093–107. https://doi.org/10.32604/or.2024.047257

Zhang J, Liu J, Yue Y, Wang L, He Q, Xu S, et al. The immunotoxin targeting PRLR increases tamoxifen sensitivity and enhances the efficacy of chemotherapy in breast cancer. J Exp Clin Cancer Res. 2024 Jun 20;43(1):173. https://doi.org/10.1186/s13046-024-03099-4

Nurkolis F, Kurniatanty I, Wiyarta E, Permatasari HK, Mayulu N, Taslim NA, et al. Identification of novel functional compounds from forest onion and its biological activities against breast cancer. J Agric Food Res [Internet]. 2024 Dec [cited 2025 Jun 10];18(101362). https://doi.org/10.1016/j.jafr.2024.101362

Silva RMG da, Alves CP, Barbosa FC, Santos HH, Adão KM, Granero FO, et al. Antioxidant, antitumoral, antimetastatic effect and inhibition of collagenase enzyme activity of Eleutherine bulbosa (Dayak onion) extract: In vitro, in vivo and in silico approaches. J Ethnopharmacol. 2024 Jan 10;318(Pt B):117005. https://doi.org/10.1016/j.jep.2023.117005

Arbain D, Sriwahyuni K, Susanti D, Taher M. Genus Eleutherine: A review of its distribution, traditional uses, phytochemistry, biological activities and its interchangeable common names. South Afr J Bot. 2022 Nov;150:731–43. https://doi.org/10.1016/j.sajb.2022.08.022

Kamarudin AA, Sayuti NH, Saad N, Razak NAA, Esa NM. Eleutherine bulbosa (Mill.) Urb. Bulb: Review of the Pharmacological Activities and Its Prospects for Application. Int J Mol Sci. 2021 Jun 23;22(13):6747. https://doi.org/10.3390/ijms22136747

Laskar YB, Bhattacharjee K, Nath M, Choudhury Y, Mazumder PB, Talukdar AD. Protective Effects of Pelargonidin against DMBA-Induced Mammary Tumorigenesis in BALB/c Mice through Reduced Oxidative Stress and Lipid Anomalies. Nutr Cancer. 2023 Aug 9;75(7):1579–99. https://doi.org/10.1080/01635581.2023.2219027

Efrem DG, Ilmiawan MI, Pratiwi SE. Chemopreventive effect of dayak onion [Eleutherine bulbosa, Mill. (Urb)] against 7,12-dimethylbenz [α] anthracene (DMBA)-induced breast cancer in rats: study on cancer antigen 15-3 (CA 15-3). Indones J Biomed Clin Sci [Internet]. 2024 Aug 21 [cited 2025 May 4];56(3). https://doi.org/10.22146/inajbcs.v56i3.12245

Moghadam RH, Rouzbahani M, Salehi N, Sadeghi M. Association between blood Interleukin-10 level in coronary artery disease: A systematic review, meta-analysis, and network analyses. Biomed Res Ther. 2024 Jul 31;11(7):6603–21. https://doi.org/10.15419/bmrat.v11i7.907

Anton B, Department of Pharmacology and Toxicology, Faculty of Pharmacy, Universitas Indonesia, Depok, Indonesia, Delvika Yessi C, Department of Pharmacology and Toxicology, Faculty of Pharmacy, Universitas Indonesia, Depok, Indonesia. Dayak Onions (Eleutherine bulbosa (Mill.) Urb.) Bulbs Extracts Reduce the Blood Pressure of Ovariectomized Rats. J Nat REMEDIES. 2018 Sep 10;18(2):49–54. https://doi.org/10.18311/jnr/2018/21556

Matariek G, Teibo JO, Elsamman K, Teibo TKA, Olatunji DI, Matareek A, et al. Tamoxifen: The Past, Present, and Future of a Previous Orphan Drug. Eur J Med Health Sci. 2022 May 24;4(3):1–10. https://doi.org/10.24018/ejmed.2022.4.3.1124

Zhang L, Virgous C, Si H. Synergistic anti-inflammatory effects and mechanisms of combined phytochemicals. J Nutr Biochem. 2019 Jul;69:19–30. https://doi.org/10.1016/j.jnutbio.2019.03.009

Huang H, Zhou J, Chen H, Li J, Zhang C, Jiang X, et al. The immunomodulatory effects of endocrine therapy in breast cancer. J Exp Clin Cancer Res. 2021 Jan 7;40(1):19. https://doi.org/10.1186/s13046-020-01788-4

Sfogliarini C, Pepe G, Dolce A, Della Torre S, Cesta MC, Allegretti M, et al. Tamoxifen Twists Again: On and Off-Targets in Macrophages and Infections. Front Pharmacol. 2022 Mar 30;13:879020. https://doi.org/10.3389/fphar.2022.879020

Kubatka P, Koklesova L, Mazurakova A, Brockmueller A, Büsselberg D, Kello M, et al. Cell plasticity modulation by flavonoids in resistant breast carcinoma targeting the nuclear factor kappa B signaling. Cancer Metastasis Rev. 2024 Mar;43(1):87–113. https://doi.org/10.1007/s10555-023-10134-x

Wang S, Wang J, Chen Z, Luo J, Guo W, Sun L, et al. Targeting M2-like tumor-associated macrophages is a potential therapeutic approach to overcome antitumor drug resistance. Npj Precis Oncol. 2024 Feb 10;8(1):31. https://doi.org/10.1038/s41698-024-00522-z

Yen C, Zhao F, Yu Z, Zhu X, Li CG. Interactions Between Natural Products and Tamoxifen in Breast Cancer: A Comprehensive Literature Review. Front Pharmacol. 2022 Jun 2;13:847113. https://doi.org/10.3389/fphar.2022.847113

Sun Z, Li Q, Zhang J, Sun Z, Wu H, Liang H, et al. Phenolic constituents with antibacterial activity from Eleutherine bulbosa. Fitoterapia. 2024 Jan 1;172:105787. https://doi.org/10.1016/j.fitote.2023.105787

Zakaria NH, Saad N, Che Abdullah CA, Mohd. Esa N. The Antiproliferative Effect of Chloroform Fraction of Eleutherine bulbosa (Mill.) Urb. on 2D- and 3D-Human Lung Cancer Cells (A549) Model. Pharmaceuticals. 2023 Jun 28;16(7):936. https://doi.org/10.3390/ph16070936

Mulder TAM, de With M, del Re M, Danesi R, Mathijssen RHJ, van Schaik RHN. Clinical CYP2D6 Genotyping to Personalize Adjuvant Tamoxifen Treatment in ER-Positive Breast Cancer Patients: Current Status of a Controversy. Cancers. 2021 Jan;13(4):771. https://doi.org/10.3390/cancers13040771

Authors

Rahmi
andi nilawati usman
andinilawati@pasca.unhas.ac.id (Primary Contact)
Risfah Yulanty
Stang
Andi Ariyandy
1.
Rahmi, usman andi nilawati, Yulanty R, Stang, Ariyandy A. Regulation of IL-10 by Herbal and Hormonal Therapy: The Impact of Eleutherine Bulbosa and Tamoxifen in an Experimental Breast Cancer Model: Effects of Eleutherine bulbosa–Tamoxifen on interleukin-10. Arch Breast Cancer [Internet]. [cited 2026 Jan. 12];13(1). Available from: https://www.archbreastcancer.com/index.php/abc/article/view/1174

Article Details